Human PF4 (CXCL4) Recombinant
$70.00 – $2,700.00
| accession | P02776 |
| Source | Optimized DNA sequence encoding Human PF4 CXCL4 mature chain was expressed in Escherichia Coli. |
| Molecular weight | Native human PF4 is generated by the proteolytic removal of the signal peptide and propeptide. The molecule has a calculated molecular mass of approximately 8kDa. Recombinant PF4 is a monomer protein consisting of 70 amino acid residue subunits, and migrates as an approximately 8kDa protein under non-reducing and reducing conditions in SDS-PAGE. |
| Purity | >95%, as determined by SDS-PAGE and HPLC |
| Biological Activity | Determined by its ability to inhibit human FGF-basic-dependent proliferation of NR6R-3T3 mouse fibroblasts. The ED50 for this effect is typically-15 μg/mL. |
| Protein Sequence | MSSAAGFCAS RPGLLFLGLL LLPLVVAFAS AEAEEDGDLQ CLCVKTTSQV RPRHITSLEV IKAGPHCPTA QLIATLKNGR KICLDLQAPL YKKIIKKLLE S |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg). |
| Presentation | Recombinant PF4/CXCL4 was lyophilized from a 0.2μm filtered concentrated (1mg/ml) solution inmM PB,1.5M NaCl pH.4. |
| Reconstitution | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers |
| Storage | The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. |
| Usage | This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes. |
| Biological Process | Chemotaxis |
| Molecular function | Cytokine |
| Molecular function | Heparin-binding |
Methods
PF4, collagen type I and IP-10 present in PEA material.
|
PF4, collagen type I and IP-10 present in PEA material.
|